ALZN Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Alzamend Neuro Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerALZN

Market Cap4.5M

Cash RunwayRunway < 6 months

Next Catalyst2026-12

Public Research Snapshot

Alzamend Neuro Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for AL001 in Alzheimer's Disease | Healthy Non-elderly and Elderly Adults (Pivotal).

Pipeline

Asset	Indication	Modality	Stage	Public Note
AL001	Alzheimer's Disease \| Healthy Non-elderly and Elderly Adults	n/a	Pivotal	Public pipeline row
ALZN002 (autologous DCs pulsed with E22W mutant peptide).	Alzheimer Disease	Peptide	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-12	AL001	Low
Clinical Trial Completion	2028-03-03	ALZN002 (autologous DCs pulsed with E22W mutant peptide).	Low
Topline Data	March 2026	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05363293	Phase 1 \| Phase 2	COMPLETED	65	2023-04-14
NCT06921590	Phase 1	ACTIVE_NOT_RECRUITING	6	2025-12
NCT07540338	Phase 1 \| Phase 2	RECRUITING	20	2026-12
NCT05834296	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	30	2028-03-03

Scientific Context

catalyst_type | Topline Data
catalyst_window | March 2026
literature_publication | Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment.
literature_publication | Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
literature_publication | Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.

Want the full ALZN research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.